Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733075 | 1.00 | PPARA (0.58) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL1731144 | 1.00 | PPARA (0.58) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL12305797 | 0.90 | PPARA (0.56) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL5639231 | 0.90 | PPARA (0.56) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL3873538 | 0.90 | PPARA (0.56) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL6318882 | 0.90 | SYK (0.58) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL18256464 | 0.90 | SYK (0.58) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL2869086 | 0.89 | PPARA (0.55) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL2869084 | 0.89 | PPARA (0.55) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL1561964 | 0.88 | PPARA (0.59) | PPARASYKCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100364974-C | Method for synthesis of (2s,3as,7as)-perhydroindole-2- carboxylic acid and esters thereof, and use in the synthesis of perindopril | SERVIER LAB (FR) | 2008-01-30 | — | — | CN | disclosed |
| CN-1331883-C | Method for synthesis of (2s,3as,7as)-1-((s)-alanyl)-octahydro-1h-indole-2-carboxylic acid derivatives and use in the synthesis of perindopril | SERVIER COURBEVOIE LAB (FR) | 2007-08-15 | — | — | CN | disclosed |
| CN-1326871-C | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | SERVIER LAB (FR) | 2007-07-18 | — | — | CN | disclosed |
| US-7157485-B2 | Method for synthesizing derivatives of (2S,3AS,7AS)-1-[(S)-alanyl]-octahydro,-1H-indole-2-carboxylic acid and the use thereof for perindopril synthesis | LES LABORATOIRES SERVIER (FR) | 2007-01-02 | — | — | US | disclosed |
| US-20060149082-A1 | Novel method for synthesising derivatives of (2s,3as,7as)-1-[(s)-alanyl]-octahydro,-1h-indole-2-carboxylic acid and the use thereof for perindopril synthesis | LES LABORATOIRES SERVIER (FR) | 2006-07-06 | — | — | US | disclosed |
| CN-1753907-A | Method for synthesis of (2s,3as,7as)-1-((s)-alanyl)-octahydro-1h-indole-2-carboxylic acid derivatives and use in the synthesis of perindopril | SERVIER COURBEVOIE LAB (FR) | 2006-03-29 | — | — | CN | disclosed |
| CN-1753869-A | Method for synthesis of (2s,3as,7as)-perhydroindole-2- carboxylic acid and esters thereof, and use in the synthesis of perindopril | SERVIER LAB (FR) | 2006-03-29 | — | — | CN | disclosed |
| CN-1753906-A | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | SERVIER LAB (FR) | 2006-03-29 | — | — | CN | disclosed |
| US-6465495-B1 | INHIBITING DISEASE STATES ASSOCIATED WITH PROTEIN PROTEIN INTERACTION MEDIATED BY A SH2 OR SH3 DOMAIN OR A TYROSINE PHOSPHATASE SUCH AS ALLERGIES, ASTHMA, ANEMIA, AUTOIMMUNE DISEASES, CANCER, INFLAMMATORY DISEASES, OSTEOPOROSIS | OSI PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149082-A1 | Novel method for synthesising derivatives of (2s,3as,7as)-1-[(s)-alanyl]-octahydro,-1h-indole-2-carboxylic acid and the use thereof for perindopril synthesis | AGTR1, CYP2S1, PAH | PPARA 1858/4885SYK 3774/4885CTSS 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.